Get Support

Learn Mode

SRRK - Scholar Rock Holding Corp

6

$49.35

$0.19 (0.386%)

At market close

$49.81

$0.46 (0.934%)

After Hours 4/1/26, 11:17 PM

2.43/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

SRRK

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$5.67B

Industry

Biotechnology

EPS (TTM)

-$3.13

P/E (TTM)

0.00

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

0.00

P/B

23.09

Diluted Shares

120.51M

Ex-Dividend

--

Next Earnings

05-12

Forward P/E

0.00

Payout Ratio

--

P/FCF (TTM)

0.00

FCF Yield

--

Earnings Yield

-6.67%

52 Week Range

Score Card

Explore Scores Tab

2.43

Bad

Scholar Rock Holding Corp has negative free cash flow of -300.64M, which means it is currently losing money. Also, it has a current cash runway of 14.67 months. The cash runway is the amount of time the business has at its current burn rate before it will need to take on debt or dilute shareholders to raise more money.

Valuation Model

Key Score

3.00

Average

Management

1.00

Very Bad

Growth

--

--

Profitability

5.00

Very Good

Fin. Health

5.00

Very Good

Dividends

--

--

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-31 07:14:27

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 13:02:05

Form 8-K/A

(Amendment) Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-03 16:30:41

Form S-8

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Filed on 2026-03-03 07:20:55

Form 10-K

Annual financials report pursuant to Section 13 or 15(d)

Filed on 2026-03-03 07:16:38

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-03 07:14:35

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-25 17:55:24

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-02-23 16:05:22

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-19 16:30:14

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-19 16:30:12

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-19 16:30:07

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-19 16:30:05

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$73.50

48.9%

Avg:

$56.81

15.1%

Low:

$48.48

-1.8%

(% change is relative to the current stock price: $49.35)

Analyst Recommendations

Go to Analyst Tab

4.36

Very Good

41%

Strong Buy (9)

55%

Buy (12)

5%

Hold (1)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://scholarrock.com/
Address
301 Binney Street, 3rd Floor, Cambridge MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1727196

Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 289 full-time employees. The company went IPO on 2018-05-24. The company is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

IPO Date

2018-05-24

Industry

Biotechnology

Total Employees

289

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences